DPT-1

Diabetes Prevention Trial of Type 1 Diabetes

The primary objective of this multicenter randomized, controlled clinical trial is to determine whether it is possible to delay or prevent the clinical onset of type 1 diabetes through daily doses of insulin in individuals determined to be at risk for the disease. DPT-1 is sponsored by the National Institutes of Health, Juvenile Diabetes Foundation International, and the American Diabetes Association. Nine medical centers and more than 350 clinics throughout the United States and Canada are screening volunteers.

Animal research and small studies in people indicated that small, regular doses of insulin could prevent or delay type 1 diabetes in those at risk. One DPT-1 trial tested whether low-dose insulin injections could prevent or delay the development of type 1 diabetes in people at high risk for developing type 1 diabetes within 5 years. The other was an oral insulin trial that sought to prevent type 1 diabetes in people with a moderate risk for developing diabetes.

Sites Include:

  • Childrens Hospital of Los Angeles, Division of Endocrinology, Los Angeles, CA
  • Stanford University, Standard, CA
  • University of California-San Francisco, San Fransisco, CA
  • University of Colorado Barbara Davis Center for Childhood Diabetes, Denver, CO
  • University of Florida Diabetes Research Center, Gainesville, FL
  • University of Miami School of Medicine, Miami, FL
  • Joslin Diabetes Center, Boston, MA
  • University of Minnesota, Minneapolis, MN
  • Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, New York
  • Children's Hospital of Pittsburgh, Dept/Pediatric Endocrinology, Pittsburgh, PA
  • University of Texas, Children's Medical Center, Dallas, TX
  • Virginia Mason Research Center, Seattle, WA
  • Hospital for Sick Children, Division of Endocrinology, Toronoto, ON, Canada

On the Web: Clinical Trials | dpt1.epi.usf.edu